INmune Bio Inc (INMB) Stock Analysis

Verdict: HOLD

Clinical momentum in Alzheimer’s imaging data provides a speculative floor, but a 12-month cash runway necessitates near-term dilution.

Investment score: 62/100

Analysis as of

Is INmune Bio Inc stock worth reviewing? AI model thesis

INmune Bio is a high-risk, high-reward biotech play currently trading at a deep discount to analyst fair value while reporting positive biomarker data in Alzheimer's.

7-factor investment score

INmune Bio Inc opportunities and risks

What speaks for INMB

What speaks against INMB

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
INMBn/a0.0xn/a0.0%0.0%-40.3%
ATYRn/a280.9xn/a-11754.7%-36857.4%-111.1%
TILn/a0.0xn/a0.0%0.0%-64.6%
XLOn/a1.1x2.8x70.7%-58.5%-95.9%
CRVOn/a102.5xn/a100.0%-9311.6%-83.4%
MGXn/a2.1xn/a-16.4%-384.6%-183.1%
Peer mediann/a2.1xn/a0.0%-384.6%-95.9%

Frequently asked questions about INmune Bio Inc (INMB)

Is INMB stock a good investment?

The cached TradeMates AI model rates INmune Bio Inc as HOLD with an investment score of 62/100. INmune Bio is a high-risk, high-reward biotech play currently trading at a deep discount to analyst fair value while reporting positive biomarker data in Alzheimer's. This is algorithmic model output, not personal investment advice.

Is INMB stock a buy?

The TradeMates model verdict for INMB is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.